<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-3918 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-3918</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-3918</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-94.html">extraction-schema-94</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <p><strong>Paper ID:</strong> paper-261673400</p>
                <p><strong>Paper Title:</strong> <a href="https://assets.cureus.com/uploads/review_article/pdf/180774/20230909-7769-9g93qg.pdf" target="_blank">Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</a></p>
                <p><strong>Paper Abstract:</strong> The hunt for early Alzheimer's disease detection has created cutting-edge diagnostic instruments with enormous promise. This article examines the many facets of these developments, focusing on how they have revolutionised diagnosis and patient outcomes. These tools make it possible to detect tiny brain changes even before they give birth to clinical symptoms by combining cutting-edge biomarkers, neuroimaging methods, and machine-learning algorithms. A significant opportunity for therapies that can slow the course of the disease exists during this early detection stage. Additionally, these cutting-edge techniques improve diagnostic precision, objectivity, and accessibility. Liquid biopsies and blood-based biomarkers provide non-invasive alternatives, filling accessibility gaps in diagnosis. While issues with standardisation, ethics, and data integration continue, collaboration within research, clinical practice, and policy realms fuels positive developments. As technology advances, the way towards better Alzheimer's diagnosis becomes more evident, giving patients and families dealing with this difficult illness fresh hope. The synergy between scientific advancement and compassionate treatment is crucial for improving Alzheimer's disease diagnosis, as this paper emphasises.</p>
                <p><strong>Cost:</strong> 0.016</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e3918.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e3918.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Aβ accumulation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Amyloid-beta (Aβ) accumulation / amyloid plaques</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Extracellular aggregation of amyloid-β peptides into plaques in the brain proposed to initiate or drive Alzheimer's disease pathology and to be detectable by CSF Aβ42, amyloid PET, and blood Aβ assays.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Accumulation and aggregation of amyloid-beta peptides (notably altered Aβ42 levels) forming extracellular plaques that contribute to neuronal dysfunction and Alzheimer pathology (amyloid cascade hypothesis).</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review cites multiple human biomarker and imaging studies: lowered CSF Aβ42 in AD patients and in early disease; amyloid PET tracers (PiB, florbetapir, florbetaben, flutemetamol) visualize cortical amyloid deposits and distinguish AD from controls; meta-analyses report amyloid positivity in dementia syndromes and also in asymptomatic individuals. Evidence comes from human observational and imaging studies (references cited: CSF and PET studies, meta-analyses). Counter-evidence noted in literature referenced (amyloid present in some cognitively normal individuals) and discussion of 'progress and problems' with the amyloid hypothesis.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>CSF Aβ42 quantification, amyloid PET imaging, blood/plasma Aβ assays (Aβ42/Aβ40 ratios)</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Decreased CSF Aβ42; increased cortical amyloid PET tracer uptake; altered plasma Aβ42/Aβ40 ratio</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>From paper's summary table: PET (amyloid) sensitivity range 70-90%, specificity 90-95%; CSF analysis sensitivity 85-90%, specificity 90-95%; blood-based markers (Aβ assays) reported in review with sensitivity range 70-80% and specificity 80-90% (variable across studies).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Preclinical and prodromal/MCI stages (can be positive before clinical symptoms); used for differential diagnosis in symptomatic stages as well.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review summarizing human imaging (PET) and CSF biomarker studies, meta-analyses and observational cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Amyloid positivity occurs in some cognitively normal older adults (limits specificity for clinical dementia); variability between assays and centres; need for standardisation; PET is costly and involves radiation; CSF requires invasive lumbar puncture; blood Aβ assays require further validation and harmonisation.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3918.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e3918.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Tau pathology</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tau protein hyperphosphorylation and neurofibrillary tangles</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Intracellular aggregation of hyperphosphorylated tau into neurofibrillary tangles that correlate with neural dysfunction and clinical severity and are measurable via CSF p-tau and tau PET imaging.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Hyperphosphorylation and aggregation of tau protein forming neurofibrillary tangles driving neuronal dysfunction and correlating with clinical progression.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Paper cites that elevated CSF total tau (t-tau) and phosphorylated tau (p-tau) are associated with Alzheimer's pathology; tau PET tracers (e.g., 18F-AV-1451/flortaucipir, 18F-MK-6240) visualize tau aggregates and correlate with disease severity. Evidence comes from human CSF biomarker studies and tau PET imaging cohorts referenced in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>CSF t-tau and p-tau measurements; tau PET imaging using tau-selective radiotracers; emerging blood p-tau assays (e.g., p-tau181).</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Elevated CSF t-tau and p-tau; increased regional tau PET signal; increased plasma p-tau181 correlated with PET measures.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>CSF analysis sensitivity reported 85-90% and specificity 90-95% (per table). Plasma p-tau markers reported in cited studies as correlating with PET and clinical severity (no single unified metric in the review; CSF/PET generally high diagnostic value).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Effective in preclinical-to-MCI and symptomatic stages; CSF/p-tau and tau PET can indicate tau pathology that correlates with advancing disease.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review of human biomarker and PET imaging studies.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Need for standardisation of assays and PET quantification; availability and cost of tau PET; blood p-tau assays require further validation across cohorts; some tracers have off-target binding.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3918.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e3918.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neuroinflammation & synaptic dysfunction</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuroinflammatory processes and synaptic dysfunction</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Inflammatory responses and synaptic pathology (including markers of synaptic dysfunction) are proposed contributors and downstream mediators of neuronal loss in Alzheimer's disease, and are being explored as biomarkers (e.g., neurogranin, inflammatory markers).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Chronic neuroinflammation and synaptic dysfunction contributing to neurodegeneration and cognitive decline in Alzheimer's disease.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review notes ongoing research into neuroinflammatory markers and synaptic dysfunction markers in CSF (e.g., neurogranin cited in references) as correlates of pathology; evidence primarily from human fluid biomarker studies showing associations between such markers and disease status/progression.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>CSF biomarkers (neurogranin, inflammatory markers), exploratory blood/exosomal markers of synaptic proteins and inflammation.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>CSF neurogranin, inflammatory markers; altered exosomal synaptic proteins detected in plasma exosome studies.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Not quantified in a single metric in this review; considered promising adjunctive biomarkers but requiring further validation.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Preclinical and early symptomatic stages for risk stratification and monitoring progression.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review summarising human CSF and plasma/exosome biomarker research.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Markers are less disease-specific, variation across assays, early-stage research; need longitudinal validation and standardised assays.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3918.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e3918.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Vascular factors</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cerebrovascular abnormalities and vascular contributions</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Vascular abnormalities (impaired perfusion, microvascular disease) are proposed contributors or modifiers of Alzheimer's disease risk and progression and are assessed via imaging and vascular biomarkers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Cerebrovascular disease and vascular dysfunction acting as contributors or modifiers of AD pathology and cognitive decline.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review states vascular markers are under study as biomarkers; SPECT and other perfusion imaging show regional hypoperfusion in AD; vascular abnormality biomarkers are mentioned as under investigation. Evidence comes from human imaging and biomarker studies discussed in the literature.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>SPECT perfusion imaging, MRI for vascular lesions, fluid biomarkers of vascular injury (research-stage).</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Regional decreased blood flow on SPECT, MRI-visible vascular lesions/microinfarcts, vascular-related fluid markers (research-stage).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>SPECT and vascular MRI add diagnostic information but specific sensitivity/specificity not consolidated in this review; overall imaging sensitivity/specificity for neuroimaging per table: MRI sensitivity ~85%, specificity variable.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Useful for differential diagnosis and as a modifier in MCI and dementia stages; vascular contributions may be relevant at all stages.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review of human imaging and biomarker studies.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Vascular findings are not specific to AD; comorbidity with aging and other cerebrovascular diseases complicates interpretation; heterogeneity of measures.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3918.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e3918.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>APOE4</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>APOE ε4 allele (genetic risk factor)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The APOE ε4 allele is a well-established genetic risk factor that increases risk and accelerates pathophysiological changes in Alzheimer's disease, including effects on amyloid and functional connectivity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Genetic risk conferred by the APOE ε4 allele that influences amyloid deposition, neural network connectivity, and disease susceptibility.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review references studies linking APOE4 to disrupted resting-state fMRI connectivity even in absence of amyloid or decreased CSF Aβ42, indicating genetic impact on brain function; evidence from human imaging/genetic association studies.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Genotyping for APOE allele; used as risk stratification variable in research and sometimes clinical assessment.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Presence of APOE ε4 allele detected by DNA genotyping; associated with altered fMRI connectivity patterns and increased amyloid risk.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Genotyping yields definitive allele status (high analytic accuracy). As a predictor of AD it confers increased risk but is neither necessary nor sufficient; predictive value depends on age and other biomarkers.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Risk factor relevant preclinically and across disease course; used for stratification in preclinical studies.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Human genetic and imaging association studies reviewed.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>APOE4 increases risk but not determinative; many APOE4 carriers remain cognitively normal and AD occurs without APOE4; utility is in stratification rather than diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3918.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e3918.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CSF biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cerebrospinal fluid biomarkers (Aβ42, t-tau, p-tau, NfL, neurogranin)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Measurement of disease-related proteins in CSF — decreased Aβ42 and increased total and phosphorylated tau — provides biochemical evidence of AD pathology and is used clinically and in research to aid early diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Not a cause itself; CSF biomarker profile (low Aβ42, high t-tau/p-tau) is interpreted as reflecting underlying amyloid and tau pathophysiology in Alzheimer’s disease.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Multiple human CSF studies cited show typical AD pattern: low CSF Aβ42 and high t-tau/p-tau correlate with clinical diagnosis and conversion from MCI to AD. CSF NfL and neurogranin are cited as additional markers of neurodegeneration and synaptic dysfunction respectively.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Lumbar puncture with laboratory quantification of CSF Aβ42, t-tau, p-tau, NfL, neurogranin.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Low CSF Aβ42; elevated CSF t-tau and p-tau; elevated NfL; elevated neurogranin in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper's table summarises CSF analysis sensitivity 85-90% and specificity 90-95%.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Preclinical, prodromal (MCI), and symptomatic stages; changes can precede overt dementia.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review summarising human clinical biomarker studies and multicentre CSF feasibility studies.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Invasive lumbar puncture with risks and variable patient acceptance; inter-lab variability and need for assay standardisation; requirement for specialised labs; not widely available in all settings.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3918.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e3918.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Amyloid PET</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Amyloid positron emission tomography imaging (PiB, florbetapir, florbetaben, flutemetamol)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Molecular imaging using radiotracers that bind Aβ plaques to visualize and quantify amyloid burden in vivo, aiding early detection and differential diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Used to detect amyloid plaque burden that is hypothesised to be a central pathological mechanism in Alzheimer's disease (amyloid cascade).</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Amyloid PET studies cited show tracer binding in cortical regions in AD and MCI, with studies demonstrating differentiation from controls; meta-analytic prevalence data referenced indicating amyloid presence can be detected in vivo.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PET imaging with amyloid-binding radiotracers (e.g., PiB, florbetapir, florbetaben, flutemetamol).</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Regional cortical uptake of amyloid PET tracers indicating Aβ plaque deposition.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Review table: PET (amyloid) sensitivity 70-90% and specificity 90-95% (ranges across studies/tracers).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Preclinical and prodromal stages (amyloid accumulates before symptoms) and useful in clinical differential diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review of human PET imaging trials and observational cohorts (including phase 2 tracer trials).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>High cost and limited accessibility; radiation exposure; amyloid positivity not perfectly specific for symptomatic AD; requirement for tracer availability and standardisation of quantification.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3918.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e3918.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Tau PET</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tau positron emission tomography imaging (e.g., 18F-AV-1451/flortaucipir, 18F-MK-6240)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>PET imaging with tau-selective tracers to visualize neurofibrillary tangle burden and regional tau pathology correlated with clinical stage and progression.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Detects tau aggregation, a core pathological mechanism linked to neuronal loss and clinical symptoms in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review cites tau PET tracers that selectively bind aggregated tau, enabling visualization and quantification of tau pathology in human subjects; tau PET patterns correspond to disease stage and differentiate AD from other tauopathies.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PET imaging with tau-selective radiotracers (e.g., flortaucipir, MK-6240).</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Regional tau PET signal corresponding to neurofibrillary tangle distribution.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Specific sensitivity/specificity ranges not tabulated separately in the review; described as promising complementary measure to amyloid PET and CSF tau.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Useful across prodromal and symptomatic stages; correlates with severity and progression.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review of human PET imaging studies.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Tracer availability and cost; off-target binding for some tracers; requires further longitudinal validation and standardisation.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3918.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e3918.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Blood-based biomarkers / liquid biopsy</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Blood-based biomarkers and liquid biopsy approaches (plasma Aβ, plasma p-tau, plasma/serum NfL, exosomal proteins)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Minimally invasive blood assays and liquid biopsy approaches measuring plasma Aβ species, phosphorylated tau (p-tau), neurofilament light (NfL), and exosome-derived proteins for early detection and monitoring of AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Not causal but reflect underlying amyloid, tau, and neurodegenerative processes; blood markers offer accessible proxies of CNS pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review cites emerging high-performance plasma Aβ assays (Nakamura et al.), plasma p-tau associations with PET and clinical severity (Mielke et al.), and longitudinal NfL dynamics predicting neurodegeneration (Preische et al.). Evidence primarily from human cohort and biomarker studies demonstrating correlation with CSF/PET and clinical progression.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Plasma Aβ42/Aβ40 assays, plasma p-tau181 (and other p-tau isoforms), plasma/serum NfL assays, exosomal protein isolation and analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Altered plasma Aβ ratios; elevated plasma p-tau181; increased plasma NfL; disease-related proteins in neural-derived plasma exosomes.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper's summary table: blood-based markers sensitivity range 70-80% and specificity 80-90% (varies by assay and study). Individual cited studies report high performance for some assays but require cross-cohort validation.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Potential for preclinical and early symptomatic stages; intended for screening and longitudinal monitoring.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review of human plasma biomarker studies and proof-of-concept/validation cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Inter-assay variability and limited harmonisation across platforms; need large-scale longitudinal validation; biological variability and lower signal-to-noise relative to CSF; clinical cutoffs and reimbursement/implementation challenges.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3918.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e3918.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MRI / fMRI</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Magnetic Resonance Imaging (structural MRI, functional MRI)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Structural MRI detects brain atrophy (e.g., medial temporal/hippocampal atrophy) and exclusion of alternative causes, while resting-state and task fMRI detect functional connectivity changes (default mode network disruptions) in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Imaging signatures (atrophy, connectivity changes) are downstream manifestations of neurodegeneration and network dysfunction in Alzheimer's disease.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review cites MRI studies showing medial temporal lobe atrophy in probable AD, and fMRI studies showing default-mode network and connectivity alterations associated with AD; evidence from human structural and functional imaging cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Structural MRI volumetry (hippocampal/medial temporal atrophy), diffusion imaging, resting-state/task fMRI for connectivity, and longitudinal MRI for progression.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Hippocampal/medial temporal atrophy, cortical thinning, default-mode network connectivity disruptions.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper table: MRI sensitivity ~85% with specificity described as variable; fMRI used in research to detect early functional changes but not standardised for clinical diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Typically detects changes in MCI and dementia stages; some structural and connectivity changes can be detectable in preclinical at-risk populations.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review of human neuroimaging studies (cross-sectional and longitudinal).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Variability in acquisition/analysis pipelines; MRI changes are not specific to AD (atrophy also occurs in other conditions/aging); resource requirements and access limitations for advanced fMRI analyses.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3918.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e3918.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Cognitive tests</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cognitive assessment tools (MMSE, MoCA, ADAS-Cog, CDR)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Standardised cognitive tests and rating scales used clinically to detect cognitive impairment, stage dementia severity, and track progression in Alzheimer's disease.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Not a cause; clinical measures that detect cognitive dysfunction resulting from Alzheimer's disease pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review summarizes that instruments like MMSE, MoCA, ADAS-Cog, and CDR are widely used clinically and in trials to assess cognitive function; evidence comes from decades of clinical practice and validation studies referenced in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Pen-and-paper or digital cognitive screening tools and structured rating scales administered in clinics.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Scores on MMSE/MoCA/ADAS-Cog/CDR indicating impairment or decline (e.g., lower MMSE scores reflect greater impairment).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper table: cognitive assessment sensitivity 60-85% and specificity 70-85% (range across tests and settings).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Primarily captures MCI and dementia stages; less sensitive in earliest preclinical stages.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Clinical practice and validation studies reviewed.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Subjectivity, cultural and educational bias, inter-rater variability, limited sensitivity for very early disease; cannot directly measure underlying pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3918.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e3918.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Machine learning</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Machine learning algorithms applied to neuroimaging and multimodal data</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Algorithmic models (e.g., SVM, random forest, graph-based classifiers) trained on imaging and biomarker data to identify complex patterns for early AD detection and classification.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Not causal; computational approach to detect patterns produced by disease mechanisms (amyloid/tau/neurodegeneration) across multimodal data.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review cites studies where machine learning applied to fMRI and other neuroimaging data detected early functional connectivity abnormalities and classified AD vs controls; evidence includes systematic reviews of ML classification performance on neuroimaging datasets.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Supervised learning (SVM, random forest, deep learning) on MRI, fMRI, PET and biomarker datasets; multimodal fusion approaches.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Patterns of functional/structural change, combinations of imaging features and fluid biomarkers identified by classifiers.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper's summary table: machine learning sensitivity 80-90% and specificity 85-90% (reported ranges across studies).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Applied for early detection (preclinical/MCI) in research settings and for differential diagnosis in symptomatic stages.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review of algorithmic studies and meta-analyses employing human imaging and biomarker datasets.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Dependence on training data quality and representativeness, limited interpretability, potential overfitting, lack of external validation/standardisation, integration challenges for multimodal data.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics <em>(Rating: 2)</em></li>
                <li>High performance plasma amyloid-β biomarkers for Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography <em>(Rating: 2)</em></li>
                <li>Cerebrospinal fluid and plasma biomarkers in Alzheimer disease <em>(Rating: 2)</em></li>
                <li>Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis <em>(Rating: 2)</em></li>
                <li>Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Imaging beta-amyloid burden in aging and dementia <em>(Rating: 2)</em></li>
                <li>Tau PET imaging in Alzheimer's disease <em>(Rating: 2)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-3918",
    "paper_id": "paper-261673400",
    "extraction_schema_id": "extraction-schema-94",
    "extracted_data": [
        {
            "name_short": "Aβ accumulation",
            "name_full": "Amyloid-beta (Aβ) accumulation / amyloid plaques",
            "brief_description": "Extracellular aggregation of amyloid-β peptides into plaques in the brain proposed to initiate or drive Alzheimer's disease pathology and to be detectable by CSF Aβ42, amyloid PET, and blood Aβ assays.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Accumulation and aggregation of amyloid-beta peptides (notably altered Aβ42 levels) forming extracellular plaques that contribute to neuronal dysfunction and Alzheimer pathology (amyloid cascade hypothesis).",
            "cause_evidence": "Review cites multiple human biomarker and imaging studies: lowered CSF Aβ42 in AD patients and in early disease; amyloid PET tracers (PiB, florbetapir, florbetaben, flutemetamol) visualize cortical amyloid deposits and distinguish AD from controls; meta-analyses report amyloid positivity in dementia syndromes and also in asymptomatic individuals. Evidence comes from human observational and imaging studies (references cited: CSF and PET studies, meta-analyses). Counter-evidence noted in literature referenced (amyloid present in some cognitively normal individuals) and discussion of 'progress and problems' with the amyloid hypothesis.",
            "detection_method": "CSF Aβ42 quantification, amyloid PET imaging, blood/plasma Aβ assays (Aβ42/Aβ40 ratios)",
            "biomarker_or_finding": "Decreased CSF Aβ42; increased cortical amyloid PET tracer uptake; altered plasma Aβ42/Aβ40 ratio",
            "detection_performance": "From paper's summary table: PET (amyloid) sensitivity range 70-90%, specificity 90-95%; CSF analysis sensitivity 85-90%, specificity 90-95%; blood-based markers (Aβ assays) reported in review with sensitivity range 70-80% and specificity 80-90% (variable across studies).",
            "detection_stage": "Preclinical and prodromal/MCI stages (can be positive before clinical symptoms); used for differential diagnosis in symptomatic stages as well.",
            "study_type": "Review summarizing human imaging (PET) and CSF biomarker studies, meta-analyses and observational cohorts.",
            "limitations_or_counter_evidence": "Amyloid positivity occurs in some cognitively normal older adults (limits specificity for clinical dementia); variability between assays and centres; need for standardisation; PET is costly and involves radiation; CSF requires invasive lumbar puncture; blood Aβ assays require further validation and harmonisation.",
            "uuid": "e3918.0",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Tau pathology",
            "name_full": "Tau protein hyperphosphorylation and neurofibrillary tangles",
            "brief_description": "Intracellular aggregation of hyperphosphorylated tau into neurofibrillary tangles that correlate with neural dysfunction and clinical severity and are measurable via CSF p-tau and tau PET imaging.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Hyperphosphorylation and aggregation of tau protein forming neurofibrillary tangles driving neuronal dysfunction and correlating with clinical progression.",
            "cause_evidence": "Paper cites that elevated CSF total tau (t-tau) and phosphorylated tau (p-tau) are associated with Alzheimer's pathology; tau PET tracers (e.g., 18F-AV-1451/flortaucipir, 18F-MK-6240) visualize tau aggregates and correlate with disease severity. Evidence comes from human CSF biomarker studies and tau PET imaging cohorts referenced in the review.",
            "detection_method": "CSF t-tau and p-tau measurements; tau PET imaging using tau-selective radiotracers; emerging blood p-tau assays (e.g., p-tau181).",
            "biomarker_or_finding": "Elevated CSF t-tau and p-tau; increased regional tau PET signal; increased plasma p-tau181 correlated with PET measures.",
            "detection_performance": "CSF analysis sensitivity reported 85-90% and specificity 90-95% (per table). Plasma p-tau markers reported in cited studies as correlating with PET and clinical severity (no single unified metric in the review; CSF/PET generally high diagnostic value).",
            "detection_stage": "Effective in preclinical-to-MCI and symptomatic stages; CSF/p-tau and tau PET can indicate tau pathology that correlates with advancing disease.",
            "study_type": "Review of human biomarker and PET imaging studies.",
            "limitations_or_counter_evidence": "Need for standardisation of assays and PET quantification; availability and cost of tau PET; blood p-tau assays require further validation across cohorts; some tracers have off-target binding.",
            "uuid": "e3918.1",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Neuroinflammation & synaptic dysfunction",
            "name_full": "Neuroinflammatory processes and synaptic dysfunction",
            "brief_description": "Inflammatory responses and synaptic pathology (including markers of synaptic dysfunction) are proposed contributors and downstream mediators of neuronal loss in Alzheimer's disease, and are being explored as biomarkers (e.g., neurogranin, inflammatory markers).",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Chronic neuroinflammation and synaptic dysfunction contributing to neurodegeneration and cognitive decline in Alzheimer's disease.",
            "cause_evidence": "Review notes ongoing research into neuroinflammatory markers and synaptic dysfunction markers in CSF (e.g., neurogranin cited in references) as correlates of pathology; evidence primarily from human fluid biomarker studies showing associations between such markers and disease status/progression.",
            "detection_method": "CSF biomarkers (neurogranin, inflammatory markers), exploratory blood/exosomal markers of synaptic proteins and inflammation.",
            "biomarker_or_finding": "CSF neurogranin, inflammatory markers; altered exosomal synaptic proteins detected in plasma exosome studies.",
            "detection_performance": "Not quantified in a single metric in this review; considered promising adjunctive biomarkers but requiring further validation.",
            "detection_stage": "Preclinical and early symptomatic stages for risk stratification and monitoring progression.",
            "study_type": "Review summarising human CSF and plasma/exosome biomarker research.",
            "limitations_or_counter_evidence": "Markers are less disease-specific, variation across assays, early-stage research; need longitudinal validation and standardised assays.",
            "uuid": "e3918.2",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Vascular factors",
            "name_full": "Cerebrovascular abnormalities and vascular contributions",
            "brief_description": "Vascular abnormalities (impaired perfusion, microvascular disease) are proposed contributors or modifiers of Alzheimer's disease risk and progression and are assessed via imaging and vascular biomarkers.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Cerebrovascular disease and vascular dysfunction acting as contributors or modifiers of AD pathology and cognitive decline.",
            "cause_evidence": "Review states vascular markers are under study as biomarkers; SPECT and other perfusion imaging show regional hypoperfusion in AD; vascular abnormality biomarkers are mentioned as under investigation. Evidence comes from human imaging and biomarker studies discussed in the literature.",
            "detection_method": "SPECT perfusion imaging, MRI for vascular lesions, fluid biomarkers of vascular injury (research-stage).",
            "biomarker_or_finding": "Regional decreased blood flow on SPECT, MRI-visible vascular lesions/microinfarcts, vascular-related fluid markers (research-stage).",
            "detection_performance": "SPECT and vascular MRI add diagnostic information but specific sensitivity/specificity not consolidated in this review; overall imaging sensitivity/specificity for neuroimaging per table: MRI sensitivity ~85%, specificity variable.",
            "detection_stage": "Useful for differential diagnosis and as a modifier in MCI and dementia stages; vascular contributions may be relevant at all stages.",
            "study_type": "Review of human imaging and biomarker studies.",
            "limitations_or_counter_evidence": "Vascular findings are not specific to AD; comorbidity with aging and other cerebrovascular diseases complicates interpretation; heterogeneity of measures.",
            "uuid": "e3918.3",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "APOE4",
            "name_full": "APOE ε4 allele (genetic risk factor)",
            "brief_description": "The APOE ε4 allele is a well-established genetic risk factor that increases risk and accelerates pathophysiological changes in Alzheimer's disease, including effects on amyloid and functional connectivity.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Genetic risk conferred by the APOE ε4 allele that influences amyloid deposition, neural network connectivity, and disease susceptibility.",
            "cause_evidence": "Review references studies linking APOE4 to disrupted resting-state fMRI connectivity even in absence of amyloid or decreased CSF Aβ42, indicating genetic impact on brain function; evidence from human imaging/genetic association studies.",
            "detection_method": "Genotyping for APOE allele; used as risk stratification variable in research and sometimes clinical assessment.",
            "biomarker_or_finding": "Presence of APOE ε4 allele detected by DNA genotyping; associated with altered fMRI connectivity patterns and increased amyloid risk.",
            "detection_performance": "Genotyping yields definitive allele status (high analytic accuracy). As a predictor of AD it confers increased risk but is neither necessary nor sufficient; predictive value depends on age and other biomarkers.",
            "detection_stage": "Risk factor relevant preclinically and across disease course; used for stratification in preclinical studies.",
            "study_type": "Human genetic and imaging association studies reviewed.",
            "limitations_or_counter_evidence": "APOE4 increases risk but not determinative; many APOE4 carriers remain cognitively normal and AD occurs without APOE4; utility is in stratification rather than diagnosis.",
            "uuid": "e3918.4",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "CSF biomarkers",
            "name_full": "Cerebrospinal fluid biomarkers (Aβ42, t-tau, p-tau, NfL, neurogranin)",
            "brief_description": "Measurement of disease-related proteins in CSF — decreased Aβ42 and increased total and phosphorylated tau — provides biochemical evidence of AD pathology and is used clinically and in research to aid early diagnosis.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Not a cause itself; CSF biomarker profile (low Aβ42, high t-tau/p-tau) is interpreted as reflecting underlying amyloid and tau pathophysiology in Alzheimer’s disease.",
            "cause_evidence": "Multiple human CSF studies cited show typical AD pattern: low CSF Aβ42 and high t-tau/p-tau correlate with clinical diagnosis and conversion from MCI to AD. CSF NfL and neurogranin are cited as additional markers of neurodegeneration and synaptic dysfunction respectively.",
            "detection_method": "Lumbar puncture with laboratory quantification of CSF Aβ42, t-tau, p-tau, NfL, neurogranin.",
            "biomarker_or_finding": "Low CSF Aβ42; elevated CSF t-tau and p-tau; elevated NfL; elevated neurogranin in AD.",
            "detection_performance": "Paper's table summarises CSF analysis sensitivity 85-90% and specificity 90-95%.",
            "detection_stage": "Preclinical, prodromal (MCI), and symptomatic stages; changes can precede overt dementia.",
            "study_type": "Review summarising human clinical biomarker studies and multicentre CSF feasibility studies.",
            "limitations_or_counter_evidence": "Invasive lumbar puncture with risks and variable patient acceptance; inter-lab variability and need for assay standardisation; requirement for specialised labs; not widely available in all settings.",
            "uuid": "e3918.5",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Amyloid PET",
            "name_full": "Amyloid positron emission tomography imaging (PiB, florbetapir, florbetaben, flutemetamol)",
            "brief_description": "Molecular imaging using radiotracers that bind Aβ plaques to visualize and quantify amyloid burden in vivo, aiding early detection and differential diagnosis.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Used to detect amyloid plaque burden that is hypothesised to be a central pathological mechanism in Alzheimer's disease (amyloid cascade).",
            "cause_evidence": "Amyloid PET studies cited show tracer binding in cortical regions in AD and MCI, with studies demonstrating differentiation from controls; meta-analytic prevalence data referenced indicating amyloid presence can be detected in vivo.",
            "detection_method": "PET imaging with amyloid-binding radiotracers (e.g., PiB, florbetapir, florbetaben, flutemetamol).",
            "biomarker_or_finding": "Regional cortical uptake of amyloid PET tracers indicating Aβ plaque deposition.",
            "detection_performance": "Review table: PET (amyloid) sensitivity 70-90% and specificity 90-95% (ranges across studies/tracers).",
            "detection_stage": "Preclinical and prodromal stages (amyloid accumulates before symptoms) and useful in clinical differential diagnosis.",
            "study_type": "Review of human PET imaging trials and observational cohorts (including phase 2 tracer trials).",
            "limitations_or_counter_evidence": "High cost and limited accessibility; radiation exposure; amyloid positivity not perfectly specific for symptomatic AD; requirement for tracer availability and standardisation of quantification.",
            "uuid": "e3918.6",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Tau PET",
            "name_full": "Tau positron emission tomography imaging (e.g., 18F-AV-1451/flortaucipir, 18F-MK-6240)",
            "brief_description": "PET imaging with tau-selective tracers to visualize neurofibrillary tangle burden and regional tau pathology correlated with clinical stage and progression.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Detects tau aggregation, a core pathological mechanism linked to neuronal loss and clinical symptoms in AD.",
            "cause_evidence": "Review cites tau PET tracers that selectively bind aggregated tau, enabling visualization and quantification of tau pathology in human subjects; tau PET patterns correspond to disease stage and differentiate AD from other tauopathies.",
            "detection_method": "PET imaging with tau-selective radiotracers (e.g., flortaucipir, MK-6240).",
            "biomarker_or_finding": "Regional tau PET signal corresponding to neurofibrillary tangle distribution.",
            "detection_performance": "Specific sensitivity/specificity ranges not tabulated separately in the review; described as promising complementary measure to amyloid PET and CSF tau.",
            "detection_stage": "Useful across prodromal and symptomatic stages; correlates with severity and progression.",
            "study_type": "Review of human PET imaging studies.",
            "limitations_or_counter_evidence": "Tracer availability and cost; off-target binding for some tracers; requires further longitudinal validation and standardisation.",
            "uuid": "e3918.7",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Blood-based biomarkers / liquid biopsy",
            "name_full": "Blood-based biomarkers and liquid biopsy approaches (plasma Aβ, plasma p-tau, plasma/serum NfL, exosomal proteins)",
            "brief_description": "Minimally invasive blood assays and liquid biopsy approaches measuring plasma Aβ species, phosphorylated tau (p-tau), neurofilament light (NfL), and exosome-derived proteins for early detection and monitoring of AD.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Not causal but reflect underlying amyloid, tau, and neurodegenerative processes; blood markers offer accessible proxies of CNS pathology.",
            "cause_evidence": "Review cites emerging high-performance plasma Aβ assays (Nakamura et al.), plasma p-tau associations with PET and clinical severity (Mielke et al.), and longitudinal NfL dynamics predicting neurodegeneration (Preische et al.). Evidence primarily from human cohort and biomarker studies demonstrating correlation with CSF/PET and clinical progression.",
            "detection_method": "Plasma Aβ42/Aβ40 assays, plasma p-tau181 (and other p-tau isoforms), plasma/serum NfL assays, exosomal protein isolation and analysis.",
            "biomarker_or_finding": "Altered plasma Aβ ratios; elevated plasma p-tau181; increased plasma NfL; disease-related proteins in neural-derived plasma exosomes.",
            "detection_performance": "Paper's summary table: blood-based markers sensitivity range 70-80% and specificity 80-90% (varies by assay and study). Individual cited studies report high performance for some assays but require cross-cohort validation.",
            "detection_stage": "Potential for preclinical and early symptomatic stages; intended for screening and longitudinal monitoring.",
            "study_type": "Review of human plasma biomarker studies and proof-of-concept/validation cohorts.",
            "limitations_or_counter_evidence": "Inter-assay variability and limited harmonisation across platforms; need large-scale longitudinal validation; biological variability and lower signal-to-noise relative to CSF; clinical cutoffs and reimbursement/implementation challenges.",
            "uuid": "e3918.8",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "MRI / fMRI",
            "name_full": "Magnetic Resonance Imaging (structural MRI, functional MRI)",
            "brief_description": "Structural MRI detects brain atrophy (e.g., medial temporal/hippocampal atrophy) and exclusion of alternative causes, while resting-state and task fMRI detect functional connectivity changes (default mode network disruptions) in AD.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Imaging signatures (atrophy, connectivity changes) are downstream manifestations of neurodegeneration and network dysfunction in Alzheimer's disease.",
            "cause_evidence": "Review cites MRI studies showing medial temporal lobe atrophy in probable AD, and fMRI studies showing default-mode network and connectivity alterations associated with AD; evidence from human structural and functional imaging cohorts.",
            "detection_method": "Structural MRI volumetry (hippocampal/medial temporal atrophy), diffusion imaging, resting-state/task fMRI for connectivity, and longitudinal MRI for progression.",
            "biomarker_or_finding": "Hippocampal/medial temporal atrophy, cortical thinning, default-mode network connectivity disruptions.",
            "detection_performance": "Paper table: MRI sensitivity ~85% with specificity described as variable; fMRI used in research to detect early functional changes but not standardised for clinical diagnosis.",
            "detection_stage": "Typically detects changes in MCI and dementia stages; some structural and connectivity changes can be detectable in preclinical at-risk populations.",
            "study_type": "Review of human neuroimaging studies (cross-sectional and longitudinal).",
            "limitations_or_counter_evidence": "Variability in acquisition/analysis pipelines; MRI changes are not specific to AD (atrophy also occurs in other conditions/aging); resource requirements and access limitations for advanced fMRI analyses.",
            "uuid": "e3918.9",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Cognitive tests",
            "name_full": "Cognitive assessment tools (MMSE, MoCA, ADAS-Cog, CDR)",
            "brief_description": "Standardised cognitive tests and rating scales used clinically to detect cognitive impairment, stage dementia severity, and track progression in Alzheimer's disease.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Not a cause; clinical measures that detect cognitive dysfunction resulting from Alzheimer's disease pathology.",
            "cause_evidence": "Review summarizes that instruments like MMSE, MoCA, ADAS-Cog, and CDR are widely used clinically and in trials to assess cognitive function; evidence comes from decades of clinical practice and validation studies referenced in the paper.",
            "detection_method": "Pen-and-paper or digital cognitive screening tools and structured rating scales administered in clinics.",
            "biomarker_or_finding": "Scores on MMSE/MoCA/ADAS-Cog/CDR indicating impairment or decline (e.g., lower MMSE scores reflect greater impairment).",
            "detection_performance": "Paper table: cognitive assessment sensitivity 60-85% and specificity 70-85% (range across tests and settings).",
            "detection_stage": "Primarily captures MCI and dementia stages; less sensitive in earliest preclinical stages.",
            "study_type": "Clinical practice and validation studies reviewed.",
            "limitations_or_counter_evidence": "Subjectivity, cultural and educational bias, inter-rater variability, limited sensitivity for very early disease; cannot directly measure underlying pathology.",
            "uuid": "e3918.10",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Machine learning",
            "name_full": "Machine learning algorithms applied to neuroimaging and multimodal data",
            "brief_description": "Algorithmic models (e.g., SVM, random forest, graph-based classifiers) trained on imaging and biomarker data to identify complex patterns for early AD detection and classification.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Not causal; computational approach to detect patterns produced by disease mechanisms (amyloid/tau/neurodegeneration) across multimodal data.",
            "cause_evidence": "Review cites studies where machine learning applied to fMRI and other neuroimaging data detected early functional connectivity abnormalities and classified AD vs controls; evidence includes systematic reviews of ML classification performance on neuroimaging datasets.",
            "detection_method": "Supervised learning (SVM, random forest, deep learning) on MRI, fMRI, PET and biomarker datasets; multimodal fusion approaches.",
            "biomarker_or_finding": "Patterns of functional/structural change, combinations of imaging features and fluid biomarkers identified by classifiers.",
            "detection_performance": "Paper's summary table: machine learning sensitivity 80-90% and specificity 85-90% (reported ranges across studies).",
            "detection_stage": "Applied for early detection (preclinical/MCI) in research settings and for differential diagnosis in symptomatic stages.",
            "study_type": "Review of algorithmic studies and meta-analyses employing human imaging and biomarker datasets.",
            "limitations_or_counter_evidence": "Dependence on training data quality and representativeness, limited interpretability, potential overfitting, lack of external validation/standardisation, integration challenges for multimodal data.",
            "uuid": "e3918.11",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics",
            "rating": 2,
            "sanitized_title": "the_amyloid_hypothesis_of_alzheimers_disease_progress_and_problems_on_the_road_to_therapeutics"
        },
        {
            "paper_title": "High performance plasma amyloid-β biomarkers for Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "high_performance_plasma_amyloidβ_biomarkers_for_alzheimers_disease"
        },
        {
            "paper_title": "Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography",
            "rating": 2,
            "sanitized_title": "plasma_phosphotau181_increases_with_alzheimers_disease_clinical_severity_and_is_associated_with_tauand_amyloidpositron_emission_tomography"
        },
        {
            "paper_title": "Cerebrospinal fluid and plasma biomarkers in Alzheimer disease",
            "rating": 2,
            "sanitized_title": "cerebrospinal_fluid_and_plasma_biomarkers_in_alzheimer_disease"
        },
        {
            "paper_title": "Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis",
            "rating": 2,
            "sanitized_title": "prevalence_of_cerebral_amyloid_pathology_in_persons_without_dementia_a_metaanalysis"
        },
        {
            "paper_title": "Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "serum_neurofilament_dynamics_predicts_neurodegeneration_and_clinical_progression_in_presymptomatic_alzheimers_disease"
        },
        {
            "paper_title": "Imaging beta-amyloid burden in aging and dementia",
            "rating": 2,
            "sanitized_title": "imaging_betaamyloid_burden_in_aging_and_dementia"
        },
        {
            "paper_title": "Tau PET imaging in Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "tau_pet_imaging_in_alzheimers_disease"
        }
    ],
    "cost": 0.01618225,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations
09/09/2023</p>
<p>Anup Juganavar anupjuganavar9003@gmail.com 
Abhishek Joshi 
Tejas Shegekar </p>
<p>Jawaharlal Nehru Medical College
Datta Meghe Institute of Higher Education and Research
WardhaIND</p>
<p>Community Medicine
Jawaharlal Nehru Medical College
Datta Meghe Institute of Higher Education and Research
WardhaIND</p>
<p>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations
09/09/202347218E69FF0AE9B1BAF7105E61802AE010.7759/cureus.44937Received 08/09/2023 Review began 08/12/2023 Review ended 09/04/2023Internal MedicinePathologyRadiology biomarkersdiagnostic toolsmachine learning techniqueneuroimaging techniqueslipid biopsyalzheimer's disease
The hunt for early Alzheimer's disease detection has created cutting-edge diagnostic instruments with enormous promise.This article examines the many facets of these developments, focusing on how they have revolutionised diagnosis and patient outcomes.These tools make it possible to detect tiny brain changes even before they give birth to clinical symptoms by combining cutting-edge biomarkers, neuroimaging methods, and machine-learning algorithms.A significant opportunity for therapies that can slow the course of the disease exists during this early detection stage.Additionally, these cutting-edge techniques improve diagnostic precision, objectivity, and accessibility.Liquid biopsies and blood-based biomarkers provide noninvasive alternatives, filling accessibility gaps in diagnosis.While issues with standardisation, ethics, and data integration continue, collaboration within research, clinical practice, and policy realms fuels positive developments.As technology advances, the way towards better Alzheimer's diagnosis becomes more evident, giving patients and families dealing with this difficult illness fresh hope.The synergy between scientific advancement and compassionate treatment is crucial for improving Alzheimer's disease diagnosis, as this paper emphasises.</p>
<p>Introduction And Background</p>
<p>Alzheimer's is a common neurodegenerative condition marked by a slow loss of cognitive function and memory.It accounts for 60-80% of dementia cases, making it the most likely cause of dementia.The disease typically affects older persons, with the risk dramatically rising beyond 65 years [1].Amyloid plaques and neurofibrillary tangles build up in the brain in Alzheimer's disease, resulting in the death of neurons and malfunctioning synapses [2].Cognitive deficiencies, behavioural issues, and functional impairment brought on by these pathological changes significantly negatively influence the quality of life of the affected person and their carers.</p>
<p>The importance of early Alzheimer's disease identification cannot be overstated for several convincing reasons.To start with, early detection enables sufferers and their families to make plans and get ready for the future.It allows one to make thoughtful choices about financial, legal, and medical issues, ensuring the necessary support systems are in place.Second, early identification makes it easier to obtain various therapies and interventions that might halt the spread of the illness or lessen symptoms.Even though there is currently no cure for Alzheimer's, several drugs and treatment techniques can help control symptoms and improve general well-being.Additionally, early diagnosis makes it possible for people to participate in clinical trials and research projects meant to provide cutting-edge cures or preventative measures.People in the early stages of the disease are frequently needed for this research, and their involvement can significantly advance scientific knowledge and lead to treatment advances [1].</p>
<p>To diagnose Alzheimer's disease early, diagnostic techniques are essential.They help medical practitioners identify cognitive impairment, differentiate Alzheimer's disease from other types of dementia, and track the course of the disease.Creating and using trustworthy diagnostic tools is essential for increasing diagnostic precision, decreasing misdiagnosis rates, and permitting prompt action.The creation of diagnostic techniques for Alzheimer's disease has advanced significantly over time.Traditional approaches have been the cornerstone of diagnosis, including clinical examination, medical history assessment, cognitive testing, and brain imaging techniques [2].These techniques have drawbacks, such as late-stage findings, subjectivity, and invasive methods.Recent developments in neuroimaging methods, biomarkers, and machine learning algorithms have created novel opportunities for early detection and increased diagnostic precision [3].The emergence of the newest diagnostic techniques has the potential to transform the process of early detection of Alzheimer's disease completely.It might revolutionize clinical practice, improve patient care, and accelerate the development of new treatment procedures and preventative measures.</p>
<p>Review Methodology</p>
<p>To ensure a comprehensive exploration of diagnostic tools for early Alzheimer's disease detection, a systematic search was executed.The search was conducted in prominent databases, including PubMed, Scopus, and Web of Science, on 19 July 2023.The search utilised relevant keywords and Medical Subject Headings (MeSH) terms encompassing Alzheimer's disease, early detection, diagnostic tools, biomarkers, neuroimaging, and machine learning.The study selection adhered to predetermined criteria, focusing on studies directly related to innovative diagnostic tools for early Alzheimer's detection.Non-English studies, non-peer-reviewed articles, and those focused primarily on other neurodegenerative disorders were excluded.The initial search yielded 73 articles, and after removing duplicates, a two-phase screening process led to 68 articles for full-text review.Ultimately, 59 studies were incorporated into the final review.For visual clarity, the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram (Figure 1) below succinctly depicts the article selection process.</p>
<p>Traditional diagnostic methods for Alzheimer's disease</p>
<p>Clinical Evaluation and Medical History</p>
<p>Examining the patient's clinical condition and medical history are essential steps in diagnosing Alzheimer's disease.To learn about the patient's complaints, history of illness, and cognitive impairment, healthcare experts interview patients and their carers in-depth [4].They evaluate several things, including behavioural and functional limitations and changes in memory, language, thinking, and problem-solving skills [5].During the clinical examination, doctors may use standardised instruments to evaluate cognitive function and review for dementia, such as the Mini-Mental State Examination (MMSE) or the Montreal Cognitive Assessment (MoCA) [6].These assessments gauge a patient's cognitive ability by measuring their memory, attention, language, and visuospatial skills.During the medical history evaluation, details on the patient's current and historical health issues, usage of medications, and family history of dementia are gathered [7].A thorough medical history is necessary for a definitive diagnosis of Alzheimer's disease since other medical disorders and drugs can cause cognitive impairment or mimic its symptoms [8].</p>
<p>Brain Imaging Techniques</p>
<p>Techniques for imaging the brain are essential in diagnosing Alzheimer's disease.They help identify important disease-related biomarkers by offering insightful information on the structural and functional alterations happening in the brain [9].</p>
<p>An in-depth brain anatomy image is produced using the non-invasive imaging method known as magnetic resonance imaging (MRI).Healthcare practitioners may analyse brain shrinkage, spot anomalies, and spot structural changes linked to Alzheimer's disease because of the high-resolution pictures it gives [10].An Alzheimer's diagnosis can be supported by MRI results, which may help rule out alternative causes of cognitive impairment.The characteristic pathology of Alzheimer's disease, i.e., beta-amyloid plaques and neurofibrillary tangles, may be seen with PET scans [11].Numerous PET tracers have been designed, including florbetapir, flutemetamol, and florbetaben, to visualise and measure the amount of beta-amyloid plaques in the brain, assisting in the identification and differential diagnosis of Alzheimer's disease [12].</p>
<p>Single-photon emission computed tomography (SPECT) imaging can reveal essential details regarding regional brain function and illustrate regions with decreased blood flow or aberrant metabolism [13].In addition to assisting in the early diagnosis and tracking of the illness's course, SPECT scans can distinguish Alzheimer's disease from other forms of dementia.An understanding of brain activity and functional connectivity may be gained by functional magnetic resonance imaging (fMRI), which tracks changes in cerebral blood flow and oxygenation levels in the brain.It can assist in locating anomalies in neural networks and evaluating the functional limitations brought on by Alzheimer's disease [14].Understanding illness processes and cognitive decline, fMRI is especially helpful in examining the brain's functional alterations during cognitive activities and resting-state situations.</p>
<p>Cognitive Assessments</p>
<p>Diagnosing Alzheimer's disease and determining the degree of cognitive impairment depend heavily on cognitive exams.These tests offer quantifiable measurements of cognitive performance in various areas, assisting in identifying particular impairments and monitoring long-term improvements [15].MMSE is a frequently employed cognitive screening measure that evaluates several cognitive domains, including orientation, attention, memory, language, and visual-spatial abilities [6].A sequence of questions and exercises, including word recall, counting backwards, and obeying instructions, make up the test.A total score between 0 and 30 is possible; lower values denote more severe cognitive impairment.Compared to the MMSE, the MoCA is another often-used cognitive screening instrument offering a more thorough cognitive function assessment.Additionally, it evaluates executive skills, visuospatial skills, and attention to detail [16].Higher overall scores, which range from 0 to 30, indicate superior cognitive function.</p>
<p>A more thorough cognitive evaluation instrument created especially for Alzheimer's disease clinical trials is the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog).It assesses several areas of cognition, such as memory, language, praxis, and orientation [17].The ADAS-Cog comprises several tasks and questions; depending on the version taken, there are different score ranges.The clinical dementia rating (CDR) is a thorough evaluation instrument that rates cognitive and functional abilities across several categories.It comprises interviews with the patient and an informant (such as a family member or carer) and assigns a score of 0-5 to cognitive impairment.The CDR assists in assessing the degree of dementia and offers a comprehensive evaluation of cognitive function [18].</p>
<p>Limitations of traditional diagnostic methods</p>
<p>Late-Stage Detection</p>
<p>Conventional diagnostic techniques for Alzheimer's disease tend to identify the condition only after severe neurodegeneration and cognitive impairment, which is one of its significant drawbacks.A diagnosis can be delayed due to relying too heavily on clinical assessments, medical history evaluations, and cognitive testing, missing out on possibilities for early intervention and treatment [19].The treatment of the disease and the potential advantages of therapeutic approaches are complicated by late-stage identification.The brain may already be irreparably damaged by the time symptoms emerge and a diagnosis is obtained.Early identification is essential because it enables the application of prompt therapies and tactics to slow the course of illness and enhance patient outcomes [3].</p>
<p>Subjectivity and Variability</p>
<p>The inherent subjectivity and inconsistency in the comprehension of clinical evaluations and cognitive tests is another drawback of conventional diagnostic techniques for Alzheimer's disease.These techniques rely significantly on the professional opinion and knowledge of medical experts, which raises the possibility of inter-rater variability and subjective biases [20].Patient's symptoms and functional limitations are prone to subjective judgements during clinical examinations like interviews and observations.Due to healthcare practitioners' diverse degrees of knowledge and interpretative abilities, conflicting diagnoses and treatment suggestions may result [21].Particularly in its early stages, when symptoms may be modest, the subjectivity and unpredictability of conventional diagnostic techniques can make it difficult to accurately and reliably diagnose Alzheimer's disease.It highlights the requirement for more impartial, quantitative diagnostic instruments that can deliver reliable outcomes.</p>
<p>Expensive and Invasive Procedures</p>
<p>Conventional diagnostic techniques for Alzheimer's disease sometimes entail pricy, intrusive procedures that might be difficult to access, costly, and unpopular with patients.The brain imaging techniques for Alzheimer's include MRI, PET, and SPECT.However, these methods may be expensive and require specialised tools and skilled staff [10][11][12][13]22].Additionally, introducing radioactive tracers may be necessary for some imaging procedures, which can be hazardous and logistically challenging.A thorough evaluation of cognitive function may be obtained by neuropsychological testing; however, doing so often takes time, knowledge, and specialised tools.These tests are expensive and less available in some healthcare settings since they frequently require neuropsychologists or other specialised professionals for administration and interpretation [23].When it comes to the existence of specific biomarkers linked to Alzheimer's disease, including beta-amyloid and tau proteins, CSF examination can offer helpful information.However, getting CSF samples necessitates lumbar puncture, an intrusive procedure with potential dangers [24].Furthermore, most CSF analyses are carried out in specialised labs, raising costs and logistical difficulties.</p>
<p>Advancements in diagnostic tools for early detection</p>
<p>Biomarkers and Cerebrospinal Fluid Analysis</p>
<p>The use of biomarkers, notably through CSF examination, has been a focus of recent developments in diagnostic methods for the early diagnosis of Alzheimer's disease.These biomarkers allow for the identification of those at risk or who are just beginning to develop the disease, and they also offer important insights into the underlying pathological processes [25].The proteins tau and beta-amyloid are important indicators linked to Alzheimer's disease.The disease's distinguishing characteristics include aberrant tau protein phosphorylation and increased amounts of beta-amyloid in the brain [26].The measurement of beta-amyloid (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) proteins in CSF might provide critical diagnostic data [27].The usefulness of CSF biomarkers in distinguishing people with Alzheimer's disease from healthy controls and those with other kinds of dementia has been shown in several studies [28].Alzheimer's pathology has been linked to decreased levels of Aβ42 and elevated levels of t-tau and p-tau in the CSF, which may be beneficial in the early identification of the disease [29].More biomarkers are being researched to diagnose Alzheimer's disease early.Among these are indicators of vascular abnormalities, synaptic dysfunction, neurodegeneration, and neuroinflammatory markers [30].For instance, the neurofilament light chain (NfL) has demonstrated potential as a marker of neurodegeneration and the development of illness [31].</p>
<p>Targeted Positron Emission Tomography (PET) Imaging</p>
<p>A sophisticated diagnostic method that has shown tremendous promise in the early diagnosis of Alzheimer's disease is PET imaging.It enables the visualisation and measurement of specific molecular processes in the brain, revealing important details about the disease's underlying pathophysiology [32].For the early identification of beta-amyloid plaques, one of the indicators of Alzheimer's disease, amyloid PET imaging is beneficial.In the brain, beta-amyloid aggregates are mainly bound by radiotracers such as Pittsburgh compound B (PiB), florbetapir, florbetaben, and flutemetamol [33].Amyloid PET imaging aids in the early detection of patients with Alzheimer's disease by displaying the location and buildup of beta-amyloid.According to studies, amyloid PET imaging can help differentiate between people with Alzheimer's disease and people with other kinds of dementia or healthy controls [34].It has shown great sensitivity and specificity in identifying beta-amyloid deposition, allowing for precise diagnosis and better patient treatment [35].Tau PET imaging is another emerging application of PET technology in Alzheimer's disease diagnosis.Radiotracers such as 18F-AV-1451 (also known as T807 or flortaucipir) and 18F-MK-6240 selectively bind to tau protein aggregates, which are associated with neurofibrillary tangles in the brain.Tau pathology may be seen and quantified by tau PET imaging, which adds to our understanding of the course and severity of the illness.Alzheimer's disease can be distinguished from other neurodegenerative conditions using tau PET imaging, which has shown promise in identifying tau damage in people [36].</p>
<p>Blood-Based Biomarkers and Liquid Biopsies</p>
<p>The creation of liquid biopsies and blood-based biomarkers as non-invasive diagnostic methods for the early diagnosis of Alzheimer's disease has garnered growing interest in recent years.When compared to invasive treatments like CSF analysis or neuroimaging techniques, these methods have the benefit of being easily accessible and perhaps being less expensive.</p>
<p>There have been studies on several putative blood-based biomarkers.A number of amyloid-beta (Aβ) peptides, notably Aβ42 and Aβ40, have been investigated as blood-based biomarkers for Alzheimer's disease [37].Changes in the ratios or concentrations of these peptides in the blood may indicate an underlying amyloid condition.The production of neurofibrillary tangles in Alzheimer's disease is thought to be influenced by tau proteins, particularly phosphorylated versions (p-tau).Total tau or p-tau blood-based tests have demonstrated potential in identifying Alzheimer's disease [38].When neurons are damaged or degenerate, a protein called NfL that is present in neurons is released into the circulation.Increased NfL levels have been linked to neurodegenerative conditions such as Alzheimer's disease [39].Blood-based NfL tests are a possible indicator of illness advancement and therapeutic response.</p>
<p>Biomarkers in bodily fluids such as blood, saliva, urine, and CSF are analysed during liquid biopsies.They provide a simple, accessible method for identifying the molecular alterations linked to Alzheimer's disease.Blood samples with circulating cell-free DNA or RNA can be examined to learn about genetic or epigenetic changes particular to a specific illness [40].Potential biomarkers for Alzheimer's may include changes in certain genes or gene expression patterns.Exosomes may be separated from different bodily fluids and then examined for disease-specific indicators.Exosomal biomarkers have demonstrated potential in the early diagnosis and follow-up of neurodegenerative illnesses, including Alzheimer's disease [41].</p>
<p>Neuroimaging Techniques and Machine Learning Algorithms</p>
<p>Machine learning algorithms paired with neuroimaging methods have become effective tools for the early identification and diagnosis of Alzheimer's disease.These methods use neuroimaging's capacity to record structural, functional, and chemical changes in the brain.At the same time, machine learning techniques make it possible to analyse and comprehend intricate patterns in imaging data.An understanding of functional brain activity may be gained by fMRI, which tracks variations in blood oxygenation levels in the brain.It is able to spot changes in connectivity and activity patterns linked to Alzheimer's disease [42].Complex functional connectivity networks may be analysed using machine learning algorithms applied to fMRI data to find biomarkers that distinguish people with Alzheimer's disease from healthy controls.For instance, early functional connectivity abnormalities in Alzheimer's disease have shown promise when detected using graph-based methods in conjunction with support vector machine classifiers [43].</p>
<p>Benefits of new diagnostic tools</p>
<p>Early Identification of Alzheimer's Disease</p>
<p>There are several advantages to developing new diagnostic methods for the early diagnosis of Alzheimer's disease.Early detection enables prompt intervention and therapy, which may halt the course of the disease and enhance patient outcomes.Identifying small changes in the brain may be done using biomarkers, neuroimaging, and machine-learning techniques even before clinical symptoms appear [44].This early detection helps to focus therapies at the prodromal or preclinical periods, when they may be most successful.</p>
<p>Improved Accuracy and Objectivity</p>
<p>The new diagnostic tools use cutting-edge technology and quantitative techniques, improving the objectivity and accuracy of Alzheimer's disease diagnosis.Combining machine learning algorithms with biomarkers like beta-amyloid and tau in blood or CSF enhances the accuracy of diagnosis [45].This lessens the dependence on arbitrary clinical judgements, reducing the variation in diagnosis across various healthcare experts.</p>
<p>Non-invasive and Cost-Effective Procedures</p>
<p>There are several advantages to non-invasive diagnostic techniques, including liquid biopsies and bloodbased biomarkers.These techniques are less intrusive than more established ones like PET scans or lumbar punctures, lessening the patient's danger and pain [39].Additionally, liquid biopsies and blood-based biomarkers are more affordable and practical, enabling a larger population to receive early Alzheimer's diagnosis.</p>
<p>Facilitating Early Intervention and Treatment</p>
<p>With the rising idea of precision medicine, the availability of new diagnostic technologies allows early intervention and treatment techniques.Early detection enables medical professionals to customise therapies to specific patients depending on each patient's illness stage and features [3].This personalised strategy improves the efficacy of disease-modifying treatments and raises the chance of successful treatment results.</p>
<p>A comparison of Alzheimer's disease diagnostic tools is summarised in Table 1 [10,18,32,37,44,[46][47][48][49][50][51][52][53][54].</p>
<p>Challenges and future directions</p>
<p>Standardisation and Validation of Diagnostic Tests</p>
<p>New diagnostic procedures for Alzheimer's disease have difficulties with standardisation and validation.As more and more biomarkers, imaging methods, and machine learning algorithms are researched, it becomes increasingly important to guarantee accurate findings in various contexts.The widespread clinical application of these techniques is hampered by the absence of standardised methods for sample collection, processing, and interpretation [54].Another difficulty is confirming the validity of diagnostic tests' clinical value and accuracy.The sensitivity, specificity, and predictive usefulness of new instruments must be established through extensive longitudinal research.Developing a solid evidence basis also depends on harmonising findings from research teams and clinical locations [55].</p>
<p>Accessibility and Affordability</p>
<p>While modern diagnostic technologies show promise, it is essential to ensure they are affordable and accessible to various people.Advanced neuroimaging methods, such as targeted PET scans, can be costly and require specialised equipment and skills [56].Although liquid biopsies and blood-based biomarkers are more widely available options, their use necessitates the creation of accurate, affordable assays that can be quickly incorporated into standard clinical practice.For these innovative procedures to be widely used, insurance coverage and reimbursement challenges must be addressed [57].</p>
<p>Integration of Multiple Diagnostic Approaches</p>
<p>Integrating various methodologies brings possibilities and problems as diagnostic tools develop.Integrating biomarkers, neuroimaging, and machine learning algorithms can improve diagnostic precision, but it is crucial to consider the complexities of interpreting multimodal data [58].Creating algorithms that combine data from diverse sources and yield therapeutically beneficial findings is challenging.To achieve consistent and understandable results across research and clinical contexts, standardising techniques for integrating various diagnostic modalities is crucial [59].</p>
<p>Conclusions</p>
<p>Advanced diagnostic methods are essential for the early diagnosis of Alzheimer's disease.These methods, which combine machine learning, neuroimaging, and biomarkers, enable the detection of minor brain alterations even before symptoms appear.Early illness stages offer a critical opportunity for therapies that may slow the course of the disease.These methods improve diagnostic objectivity and accuracy while introducing more affordable and accessible choices, including blood-based biomarkers and liquid biopsies.The cooperation between researchers, physicians, and policymakers promises a bright future even though issues with standardisation, accessibility, ethics, and data integration still exist.As science and technology develop, the road to a better Alzheimer's diagnosis becomes clearer, giving patients and their families fresh hope as they deal with the difficulties of this illness.</p>
<p>FIGURE 1 :
1
FIGURE 1: The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram illustrating the process of study selection</p>
<p>tool Type Traditional/novel Sensitivity range Specificity range Advantages Challenges
Brain imaging techniquesNeuroimaging TraditionalPET (amyloid): 70-90%, MRI: 85%PET (amyloid): 90-95%, MRI: variedMolecular insightsHigh cost, radiation exposureCognitive assessmentClinicalTraditional60-85%70-85%Patient history insightsSubjectivity, cultural biasCSF analysisBiomarkersNovel85-90%90-95%Disease-specificInvasive, discomfortMachine learningAlgorithm-basedNovel80-90%85-90%Data pattern recognitionData quality, interpretabilityBlood-based markersBiomarkersNovel70-80%80-90%Non-invasive early stage diagnosisValidation, variability
2023 Juganavar et al.Cureus 15(9): e44937.DOI 10.7759/cureus.449375 of 8 Diagnostic</p>
<p>TABLE 1 : Comparison of Alzheimer's disease diagnostic tools
1
PET: positron emission tomography; CSF: cerebrospinal fluid.The table has been created by the authors.</p>
<p>Juganavar et al. Cureus 15(9): e44937. DOI 10.7759/cureus.44937
Additional Information DisclosuresConflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
What is Alzheimer's disease?. 2023. August 10, 2023</p>
<p>Alzheimer's disease: the challenge of the second century. D M Holtzman, J C Morris, A M Goate, 10.1126/scitranslmed.3002369?utm_medium=email&amp;utm_source=transactionSci Transl Med. 32011</p>
<p>Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. R A Sperling, P S Aisen, L A Beckett, 10.1016/j.jalz.2011.03.003?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 72011</p>
<p>The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. G M Mckhann, D S Knopman, H Chertkow, 10.1016/j.jalz.2011.03.005?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 72011</p>
<p>Practice parameter: diagnosis of dementia (an evidencebased review. D S Knopman, S T Dekosky, J L Cummings, 10.1212/wnl.56.9.1143?utm_medium=email&amp;utm_source=transactionReport of the Quality Standards Subcommittee of the American Academy of Neurology. 200156</p>
<p>A practical method for grading the cognitive state of patients for the clinician. M F Folstein, S E Folstein, P R Mchugh, 10.1016/0022-3956(75)90026-6?utm_medium=email&amp;utm_source=transactionJ Psychiatr Res. 121975Mini-mental state</p>
<p>The AD8: a brief informant interview to detect dementia. J E Galvin, C M Roe, K K Powlishta, 10.1212/01.wnl.0000172958.95282.2a?utm_medium=email&amp;utm_source=transactionNeurology. 652005</p>
<p>Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). R C Petersen, J C Stevens, M Ganguli, E G Tangalos, J L Cummings, S T Dekosky, 10.1212/wnl.56.9.1133?utm_medium=email&amp;utm_source=transactionReport of the Quality Standards Subcommittee of the American Academy of Neurology. 200156</p>
<p>Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond. H Hampel, S Lista, S J Teipel, 10.1016/j.bcp.2013.11.009?utm_medium=email&amp;utm_source=transactionBiochem Pharmacol. 882020. 2014</p>
<p>Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Jack CrJr, D S Knopman, W J Jagust, 10.1016/S1474-4422(09)70299-6?utm_medium=email&amp;utm_source=transactionLancet Neurol. 92010</p>
<p>Imaging beta-amyloid burden in aging and dementia. C C Rowe, S Ng, U Ackermann, 10.1212/01.wnl.0000261919.22630.ea?utm_medium=email&amp;utm_source=transactionNeurology. 682007</p>
<p>18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. R Vandenberghe, K Van Laere, A Ivanoiu, 10.1002/ana.22068?utm_medium=email&amp;utm_source=transactionAnn Neurol. 682010</p>
<p>Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. J T O'brien, S Colloby, J Fenwick, 10.1001/archneur.61.6.919?utm_medium=email&amp;utm_source=transactionArch Neurol. 612004</p>
<p>APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. Y I Sheline, J C Morris, A Z Snyder, 10.1523/JNEUROSCI.3987-10.2010?utm_medium=email&amp;utm_source=transactionJ Neurosci. 302010</p>
<p>Population-based norms for the mini-mental state examination by age and educational level. R M Crum, J C Anthony, S S Bassett, M F Folstein, 10.1001/jama.1993.03500180078038?utm_medium=email&amp;utm_source=transactionJAMA. 121993</p>
<p>MoCA: a brief screening tool for mild cognitive impairment. Z S Nasreddine, N A Phillips, V Bédirian, 10.1111/j.1532-5415.2005.53221.x?utm_medium=email&amp;utm_source=transactionThe Montreal Cognitive Assessment. 200553</p>
<p>A new rating scale for Alzheimer's disease. W G Rosen, R C Mohs, K L Davis, 10.1176/ajp.141.11.1356?utm_medium=email&amp;utm_source=transactionAm J Psychiatry. 1411984</p>
<p>Diagnosis and treatment of Alzheimer's disease: an update. E Bomasang-Layno, R Bronsther, 10.32481/djph.2021.09.009?utm_medium=email&amp;utm_source=transactionDela J Public Health. 72021</p>
<p>The Clinical Dementia Rating (CDR): current version and scoring rules. J C Morris, 10.1212/wnl.43.11.2412-a?utm_medium=email&amp;utm_source=transactionNeurology. 1993</p>
<p>Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. B Dubois, H H Feldman, C Jacova, 10.1016/S1474-4422(14)70090-0?utm_medium=email&amp;utm_source=transactionLancet Neurol. 62014</p>
<p>Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. T J Ferman, G E Smith, K Kantarci, 10.1212/01.wnl.0000436942.55281.47?utm_medium=email&amp;utm_source=transactionNeurology. 812013</p>
<p>Imaging the evolution and pathophysiology of Alzheimer disease. W Jagust, 10.1038/s41583-018-0067-3?utm_medium=email&amp;utm_source=transactionNat Rev Neurosci. 192018</p>
<p>The neuropsychological profile of Alzheimer disease . Cold Spring Harb Perspect Med. S Weintraub, A H Wicklund, D P Salmon, 10.1101/cshperspect.a006171?utm_medium=email&amp;utm_source=transaction20122</p>
<p>Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. K Blennow, H Hampel, M Weiner, H Zetterberg, 10.1038/nrneurol.2010.4?utm_medium=email&amp;utm_source=transactionNat Rev Neurol. 62010</p>
<p>From cerebrospinal fluid to blood: the third wave of fluid biomarkers for Alzheimer's disease. H Zetterberg, K Blennow, 10.3233/JAD-179926?utm_medium=email&amp;utm_source=transactionJ Alzheimers Dis. 642018</p>
<p>Parkinson's and Lewy body dementia CSF biomarkers. L Parnetti, S Paciotti, L Farotti, G Bellomo, F N Sepe, P Eusebi, 10.1016/j.cca.2019.04.078?utm_medium=email&amp;utm_source=transactionClin Chim Acta. 4952019</p>
<p>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to. J Hardy, D J Selkoe, 10.1126/science.1072994?utm_medium=email&amp;utm_source=transaction10.1126/science.1072994Juganavar et al. Cureus. 1592023</p>
<p>Cerebrospinal fluid biomarkers for Alzheimer's disease. K Blennow, H Zetterberg, 10.3233/JAD-2009-1177?utm_medium=email&amp;utm_source=transactionJ Alzheimers Dis. 182009</p>
<p>CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. N Mattsson, H Zetterberg, O Hansson, 10.1001/jama.2009.1064?utm_medium=email&amp;utm_source=transactionJAMA. 3022009</p>
<p>Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology. H Hampel, N Toschi, C Babiloni, 10.3233/JAD-179932?utm_medium=email&amp;utm_source=transactionJ Alzheimers Dis. 642018</p>
<p>Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. O Preische, S A Schultz, A Apel, 10.1038/s41591-018-0304-3?utm_medium=email&amp;utm_source=transactionNat Med. 252019</p>
<p>Molecular and imaging biomarkers in Alzheimer's disease: a focus on recent insights. C Villa, M Lavitrano, Salvatore E Combi, R , 10.3390/jpm10030061?utm_medium=email&amp;utm_source=transactionJ Pers Med. 102020</p>
<p>Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. W E Klunk, H Engler, A Nordberg, 10.1002/ana.20009?utm_medium=email&amp;utm_source=transactionAnn Neurol. 552004</p>
<p>Amyloid imaging with PET in early Alzheimer disease diagnosis. C C Rowe, V L Villemagne, 10.1016/j.mcna.2012.12.017?utm_medium=email&amp;utm_source=transactionMed Clin North Am. 972013</p>
<p>Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. W J Jansen, R Ossenkoppele, D L Knol, 10.1001/jama.2015.4668?utm_medium=email&amp;utm_source=transactionJAMA. 3132015</p>
<p>Tau PET imaging in Alzheimer's disease. N Okamura, R Harada, S Furumoto, H Arai, K Yanai, Y Kudo, 10.1007/s11910-014-0500-6?utm_medium=email&amp;utm_source=transactionCurr Neurol Neurosci Rep. 2014</p>
<p>High performance plasma amyloid-β biomarkers for Alzheimer's disease. A Nakamura, N Kaneko, V L Villemagne, 10.1038/nature25456?utm_medium=email&amp;utm_source=transactionNature. 5542018</p>
<p>Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography. M M Mielke, C E Hagen, J Xu, 10.1016/j.jalz.2018.02.013?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 142018</p>
<p>Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. N Mattsson, P S Insel, S Palmqvist, 10.15252/emmm.201606540?utm_medium=email&amp;utm_source=transactionEMBO Mol Med. 82016</p>
<p>Mitochondrial genes are altered in blood early in Alzheimer's disease. K Lunnon, A Keohane, R Pidsley, 10.1016/j.neurobiolaging.2016.12.029?utm_medium=email&amp;utm_source=transactionNeurobiol Aging. 532017</p>
<p>Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. E J Goetzl, A Boxer, J B Schwartz, E L Abner, R C Petersen, B L Miller, D Kapogiannis, 10.1212/WNL.0000000000001702?utm_medium=email&amp;utm_source=transactionNeurology. 852015</p>
<p>Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. M D Greicius, G Srivastava, A L Reiss, V Menon, 10.1073/pnas.0308627101?utm_medium=email&amp;utm_source=transactionProc Natl Acad Sci U S A. 1012004</p>
<p>Small-world networks and functional connectivity in Alzheimer's disease. Cereb Cortex. C J Stam, B F Jones, G Nolte, M Breakspear, P Scheltens, 10.1093/cercor/bhj127?utm_medium=email&amp;utm_source=transaction200717</p>
<p>Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. B Dubois, H Hampel, H H Feldman, 10.1016/j.jalz.2016.02.002?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 122016</p>
<p>NIA-AA research framework: toward a biological definition of Alzheimer's disease. Jack CrJr, D A Bennett, K Blennow, 10.1016/j.jalz.2018.02.018?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 142018</p>
<p>Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. P Scheltens, D Leys, F Barkhof, 10.1136/jnnp.55.10.967?utm_medium=email&amp;utm_source=transactionJ Neurol Neurosurg Psychiatry. 551992Atrophy of medial temporal lobes on MRI in "probable</p>
<p>K Blennow, H Hampel, 10.1016/s1474-4422(03)00530-1?utm_medium=email&amp;utm_source=transactionCSF markers for incipient Alzheimer's disease. 20032</p>
<p>Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. F H Duits, P Martinez-Lage, C Paquet, 10.1016/j.jalz.2015.08.003?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 122016</p>
<p>Random forest algorithm for the classification of neuroimaging data in Alzheimer's disease: a systematic review. A Sarica, A Cerasa, A Quattrone, 10.3389/fnagi.2017.00329?utm_medium=email&amp;utm_source=transactionFront Aging Neurosci. 92017</p>
<p>Transfer learning for Alzheimer's disease through neuroimaging biomarkers: a systematic review. D Agarwal, G Marques, I De La Torre-Díez, Franco Martin, M A , García Zapiraín, B , Martín Rodríguez, F , 10.3390/s21217259?utm_medium=email&amp;utm_source=transactionSensors (Basel). 2021</p>
<p>Brain amyloid imaging. C C Rowe, V L Villemagne, 10.2967/jnumed.110.076315?utm_medium=email&amp;utm_source=transactionJ Nucl Med. 522011</p>
<p>Conceptualizing mental disorders as deviations from normative functioning. A F Marquand, S M Kia, M Zabihi, T Wolfers, J K Buitelaar, C F Beckmann, 10.1038/s41380-019-0441-1?utm_medium=email&amp;utm_source=transactionMol Psychiatry. 242019</p>
<p>Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. H Hampel, K Bürger, S J Teipel, A L Bokde, H Zetterberg, K Blennow, 10.1016/j.jalz.2007.08.006?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 42008</p>
<p>Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. N Mattsson, N C Cullen, U Andreasson, H Zetterberg, K Blennow, 10.1001/jamaneurol.2019.0765?utm_medium=email&amp;utm_source=transactionJAMA Neurol. 762019</p>
<p>Current state of Alzheimer's fluid biomarkers. J L Molinuevo, S Ayton, R Batrla, 10.1007/s00401-018-1932-x?utm_medium=email&amp;utm_source=transactionActa Neuropathol. 1362018</p>
<p>Imaging techniques in Alzheimer's disease: a review of applications in early diagnosis and longitudinal monitoring. W M Van Oostveen, E C De Lange, 10.3390/ijms22042110?utm_medium=email&amp;utm_source=transactionInt J Mol Sci. 222021</p>
<p>Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. H Hampel, O' Bryant, S E Molinuevo, J L , 10.1038/s41582-018-0079-7?utm_medium=email&amp;utm_source=transactionNat Rev Neurol. 142018</p>
<p>Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. R Ossenkoppele, W J Jansen, G D Rabinovici, 10.1001/jama.2015.4669?utm_medium=email&amp;utm_source=transactionJAMA. 3132015</p>
<p>Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimers Dement. E C Mormino, K V Papp, D M Rentz, 10.1016/j.jalz.2017.01.018?utm_medium=email&amp;utm_source=transaction201713</p>
<p>. 10.7759/cureus.449378of8Juganavar et al. Cureus. 159e449372023</p>            </div>
        </div>

    </div>
</body>
</html>